Exclusive Summary

• • Utilizes a second-generation ER binder derived from the novel SERD Camizestrant and may demonstrate superior efficacy in both ESR1 wild-type and mutant HR+/HER2- breast cancer patients.
• • Better oral bioavailability compare with ARV-471
• • Comparable efficacy and safety profile to the SERD camizestrant at equivalent molar doses.